RRS® HA LONG LASTING Earns Top Skin Revitalization Honor at AMWC 2026

Skin Tech Pharma Group announced that RRS® HA LONG LASTING has been awarded Best Injectable in the Skin Revitalization category at the AMWC Aesthetic Medicine Awards 2026, a recognition presented during the Aesthetic & Anti-Aging Medicine World Congress (AMWC).

The award recognizes RRS® HA LONG LASTING, the company's flagship injectable treatment, for its contribution to skin revitalization and regenerative aesthetic medicine. According to Skin Tech Pharma Group, the product has been used in more than 1 million treatments worldwide since its introduction in 2021.

Recognition Highlights Growth of the Skin Builder Category

RRS® HA LONG LASTING was introduced as part of the emerging Skin Builder category, which focuses on improving skin quality while maintaining natural-looking aesthetic outcomes. The treatment is designed to support skin revitalization through approaches aimed at enhancing tissue quality and promoting healthy aging.

The company stated that the award reflects growing demand for aesthetic treatments that prioritize long-term skin health, regenerative outcomes, and subtle aesthetic enhancement rather than volumization alone.

"Receiving this award is an important milestone for us and a testament to the strength of our long-term strategy," said Márcio Rodrigues, CEO of Skin Tech Pharma Group, in a company statement. "As the aesthetic medicine landscape continues to evolve, our ambition is to lead through scientific rigor, differentiated innovation, and a deep understanding of healthcare professionals' needs. This recognition reinforces our commitment to building sustainable growth while advancing standards of care across the industry."

The AMWC Aesthetic Medicine Awards recognize innovations, products, and companies across the global aesthetics industry. For Skin Tech Pharma Group, the honor further positions RRS® HA LONG LASTING within the expanding market for regenerative and skin-quality-focused injectable treatments.

Source

Skin Tech Pharma Group press release distributed via PR Newswire, June 17, 2026.